Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
Healthcare
$1.18 +3.09%
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
52W Low $1.41High $4.34
Volume 4.26M
Average 0.64M
Balance Sheet
Inspect the capital base behind the business.
Assets
$22.82M
FY 2025 · Annual
+88.2% YoYLiabilities
$4.25M
FY 2025 · Annual
-11.1% YoYEquity
$18.56M
FY 2025 · Annual
+152.9% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.88M | 7.31M | 11.79M | 10.39M | 20.84M |
| Short-term Investments | 0 | 12.83M | 5M | 0 | 0 |
| Net Receivables | 195.45K | 103.88K | 242.58K | 765.76K | 802.69K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 640.31K | 0 | 369.89K | 275.43K |
| Total Current Assets | 37.72M | 21.09M | 17.78M | 11.6M | 22.24M |
| Property, Plant & Equipment (Net) | 1.01M | 804.31K | 585.18K | 323.33K | 409.01K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 202.61K | 213.97K | 193.38K | 134.27K | 102.84K |
| Long-term Investments | 31.28K | 1.94M | 34.02K | 31.7K | 36.3K |
| Tax Assets | (31.28K) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 53.39K | 48.32K | 17.89K | 32.11K | 33.7K |
| Total Non-current Assets | 1.26M | 3.01M | 830.46K | 521.41K | 581.84K |
| Total Assets | 38.99M | 24.1M | 18.61M | 12.12M | 22.82M |
| Account Payables | 560.48K | 1.63M | 1.32M | 946.26K | 825.03K |
| Short-term Debt | 103.83K | 108.14K | 118.8K | 110.18K | 100.87K |
| Tax Payables | 380 | 107.31K | 48.97K | 0 | 0 |
| Deferred Revenue | 266.5K | 55.18K | 1.12M | 252.21K | 0 |
| Other Current Liabilities | 380 | 364.11K | 1.38M | 18.49K | 167.89K |
| Total Current Liabilities | 2.55M | 4.13M | 4.95M | 3.91M | 3.35M |
| Long-term Debt | 590.47K | 495.26K | 449.05K | 328.33K | 300.08K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 94.79K | 47.44K | 0 |
| Other Non-current Liabilities | 329.46K | 157.58K | 307.45K | 443.62K | 390.51K |
| Total Non-current Liabilities | 1.61M | 1.09M | 1.08M | 872.99K | 901.83K |
| Total Liabilities | 4.17M | 5.22M | 6.03M | 4.78M | 4.25M |
| Common Stock | 1.19K | 1.19K | 1.62K | 2.71K | 4.21K |
| Retained Earnings | (20.93M) | (38.52M) | (60.78M) | (81.19M) | (101.36M) |
| Accumulated OCI | (90.65K) | 35.63K | 247.24K | (247.55K) | 776.87K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 34.82M | 18.88M | 12.58M | 7.34M | 18.56M |
| Total Debt | 1.61M | 1.27M | 1.03M | 653.02K | 732.07K |
| Net Debt | (35.27M) | (6.04M) | (10.77M) | (9.73M) | (20.11M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $16.5M |
| Receivables | $994.6K |
| Other Current | $687.9K |
| Total Current Assets | $18.2M |
| PP&E (Net) | $355.0K |
| Intangible Assets | $90.0K |
| Long-term Investments | $36.1K |
| Other Non-current | $35.6K |
| Total Non-current Assets | $516.7K |
| Total Assets | $18.7M |
Analysis
Selected assets total $18.7M for Latest. The largest visible component is Cash & Equivalents at $16.5M, about 88.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 17, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 30, 2026 |
How much cash does GANX have?
Gain Therapeutics, Inc. (GANX) reported $20.84M in cash and equivalents in fiscal 2025.
How much debt does GANX carry?
Gain Therapeutics, Inc. (GANX) reported $732,067.00 of total debt, with net debt of -$20.11M.
Continue the stock analysis
Jump to another research area for this company.